Thomas S.Koglman (Tom)

Associate

Cleveland + 1.216.586.1047

Connect

Share

Tom Koglman practices intellectual property law with an emphasis on patent and trade secret litigation. He has experience in a variety of fields, including chemical compositions, pharmaceuticals, biotechnology, and medical devices.

In 2016, Tom was a member of the trial team that achieved the record-breaking patent infringement verdict for Idenix Pharmaceuticals (a subsidiary of Merck & Co.), the largest infringement verdict in U.S. history. After a two-week trial, the jury ordered Gilead Sciences to pay $2.54 billion in damages for sales of sofosbuvir-based medicines, including Sovaldi and Harvoni, for its infringement of an Idenix patent related to the treatment of patients with hepatitis C virus (HCV) infection.

Prior to joining Jones Day, Tom served as a police officer for 12 years. He held various positions including patrol supervisor, patrol officer, and instructor. He was certified by the state of Ohio as a police academy instructor, firearms and use-of-force instructor, evidence technician, armorer, and SWAT officer.

Erfahrung

  • DePuy Synthes wins JMOL in patent litigation involving spinal surgery medical devicesFollowing a two-week trial, Jones Day obtained a complete victory for Johnson & Johnson subsidiaries DePuy Synthes Products, Inc.; DePuy Synthes Sales, Inc.; and Medical Device Business Services, Inc. against patent infringement claims brought by Dr. Mark Barry relating to the use of certain methods and medical instruments for spinal surgery involving DePuy's Expedium® and Viper® systems.
  • Goodyear defeats trade secrets case involving self-inflating tire technologyJones Day successfully represented Goodyear Tire & Rubber Company ("Goodyear") and its employees accused by a Czech Republic citizen and his companies of misappropriating trade secrets relating to self-inflating tire technology and incorporating the technology into several U.S. patents.
  • PI Advanced Materials obtains CAFC affirmance of summary judgment win in patent case regarding polyimide filmsJones Day successfully obtained a Federal Circuit affirmance of a summary judgment win of non-infringement on behalf of PI Advanced Materials Co., Ltd. ("PIAM", formerly SKC Kolon PI, Inc. ("SKPI")).
  • DePuy Synthes defends against multi-patent lawsuit alleging infringement against stand-alone intervertebral spinal implant productsJones Day is representing Johnson & Johnson subsidiaries DePuy Synthes Sales, Inc. and DePuy Synthes Products, Inc. in a patent infringement lawsuit brought by RSB Spine, LLC alleging that certain of its spinal implant products infringe two patents.
  • Hikvision resolves patent infringement action relating to surveillance camera devicesJones Day successfully represented Hangzhou Hikvision Digital Technology Co., Ltd. in a patent infringement action relating to remote control surveillance camera devices.
  • Idenix wins $2.54 billion jury verdict in Gilead patent dispute involving hepatitis C drugsAfter a nine day trial and less than two hours of jury deliberation, Jones Day, on behalf of Idenix Pharmaceuticals LLC (a subsidiary of Merck & Co.), won the largest patent infringement verdict in U.S. history to date, involving a multi-billion dollar patent dispute with Gilead Sciences Inc. over sofosbuvir, the active ingredient in Gilead’s hepatitis C drugs Sovaldi® and Harvoni®.
  • DePuy Synthes prevails in patent royalty dispute brought by surgeonJones Day represented Johnson & Johnson subsidiary DePuy Synthes ("DePuy") in a three-day arbitration hearing to resolve a patent royalty dispute brought by Jordan Consulting seeking more than $6.5 million in damages for breach of a product development agreement relating to DePuy's flagship posterior cervical spinal implant system, Mountaineer.
  • Kyowa Hakko Kirin and BioWa successfully enforce patent rights on antibody technologyJones Day, on behalf of Japanese life sciences company Kyowa Hakko Kirin Company, Limited ("KHK") and its wholly-owned U.S. subsidiary, BioWa, successfully settled a patent infringement suit over three of KHK's patents that underlie KHK's award-winning POTELLIGENT® technology capable of producing therapeutic antibodies with dramatically improved potency and efficacy.
  • Kyowa Hakko Kirin defeats competitors in Patent Trial and Appeal Board challenge of patents on antibody technologyOn October 23, 2017, the Patent Trial and Appeal Board ("PTAB") issued a trio of decisions, unanimously declining to institute inter partes review ("IPR") of three patents owned by a Japanese pharmaceutical company represented by Jones Day, Kyowa Hakko Kirin Co., Ltd.
  • Avid settles revived data storage patent infringement suit against Harmonic shortly before trialAfter a Jones Day team obtained a reversal of an adverse jury verdict from the United States Court of Appeals for the Federal Circuit on behalf of Avid Technology, Inc. ("Avid"), the case settled shortly before trial.
  • Wabtec acquires Faiveley Transport for $1.8 billionJones Day advised Wabtec Corporation in the acquisition of Faiveley Transport S.A., a global supplier of high added value integrated systems for the railway industry, for a total of $1.8 billion in cash and stock, including assumed debt.
  • Cleveland successfully prepares for Republican National Convention, including resolving ACLU lawsuitJones Day was engaged to represent the City of Cleveland in preparation for the Republican National Convention held in Cleveland from July 18-21, 2016.
    •

    April 2018 Blog

    Change Is Coming (Maybe): Reviewing the AIA Reviews and 101 Clarity, PTAB Litigation Blog

    February 2018 Blog

    Tribal Sovereign Immunity Doctrine Does Not Insulate Tribes From Board Actions, PTAB Litigation Blog

    May 2016 Commentary

    Deciphering Sikkelee: Implications for Aviation Claims and Product Manufacturers

    Bitte beachten Sie vor dem Versenden:

    Die Informationen auf unserer Website sind für den allgemeinen Gebrauch und stellen keine Rechtsberatung dar. Der Versand dieser E-Mail ist nicht dazu bestimmt, ein Mandatsverhältnis zu begründen, und der Erhalt dieser E-Mail stellt kein Mandatsverhältnis dar. Alles, was Sie an jemanden in unserer Kanzlei senden, ist nicht vertraulich oder privilegiert, es sei denn, wir haben zugestimmt, Sie zu vertreten. Wenn Sie diese E-Mail versenden, bestätigen Sie, dass Sie diesen Hinweis gelesen und verstanden haben.